A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis | Zendy

Kiyoyuki Furuse | Zendy; Takao Kamimori | Zendy; Mutsuto Kawahara | Zendy; Nobuhiro Kodama | Zendy; Mitsumasa Ogawara | Zendy; Shinji Atagi | Zendy; Nobuyuki Naka | Zendy; Masanori Akira | Zendy; Kaoru Kubota | Zendy

Open Access

A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis

Author(s) -

Kiyoyuki Furuse,

Takao Kamimori,

Mutsuto Kawahara,

Nobuhiro Kodama,

Mitsumasa Ogawara,

Shinji Atagi,

Nobuyuki Naka,

Masanori Akira,

Kaoru Kubota

Publication year - 1997

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1997.108

Subject(s) - vindesine , medicine , brain metastasis , lung cancer , chemotherapy , oncology , radiation therapy , cisplatin , mitomycin c , metastasis , toxicity , cancer , surgery , cyclophosphamide , vincristine

We have evaluated the feasibility, toxicity, and tumour response of concurrent whole-brain radiotherapy (WBRT) and chemotherapy with cisplatin, vindesine and mitomycin in the treatment of 33 patients with brain metastasis from non-small-cell lung cancer (NSCLC). The imaging response demonstrated that 25 patients (75.8%) responded to brain lesions, including five complete responders, and the response rate to primary lesion was 18%. The treatment improved at least one grade of performance status in 30% and of neurological functions in 55% of the patients. The major toxicity was leucopenia (> or = grade 3, 84.4%). Median survival was 9.7 months and the 1-year survival rate was 40%. Concurrent WBRT and chemotherapy can be safely administered to patients with brain metastasis from NSCLC, with a remarkable response rate, improvement of neurological functions and encouraging survival duration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research